Literature DB >> 15513975

Comparison of the effects of acarbose and metformin use on ovulation rates in clomiphene citrate-resistant polycystic ovary syndrome.

A S Sönmez1, L Yasar, K Savan, S Koç, J Ozcan, A Toklar, F Yazicioğu, A Akgün, N Sut.   

Abstract

BACKGROUND: The aim of this study was to evaluate the effects of metformin and acarbose on insulin resistance, hormone profiles and ovulation rates in patients with clomiphene citrate-resistant polycystic ovary syndrome (PCOS).
METHODS: Thirty clomiphene citrate-resistant patients were selected randomly and divided into two groups. Group I was treated with 100 mg/day clomiphene citrate and 300 mg/day acarbose 100 mg/day orally, for 3 months. Group II was treated with clomiphene citrate 100 mg/day and metformin 1700 mg/day orally, for 3 months. Serum fasting insulin and glucose, FSH, LH, estradiol, progesterone, prolactin and total testosterone levels plus body mass index (BMI) were measured before and after treatment. Follicle growth was followed by transvaginal ultrasonography.
RESULTS: LH:FSH ratio and total testosterone concentrations decreased (P<0.05) and ovulation rates increased in both groups. Reduction in weight and BMI was only significant in the acarbose group.
CONCLUSIONS: Both treatment modalities were effective in the treatment of insulin resistance and improving ovulation rates. Increase in the number of eumenorrhoeic and normoinsulinaemic cases and decrease in the number of insulin-resistant cases were significant in both groups (P<0.05). Ovulation rate was greater in the metformin group in the second month of therapy (P<0.05). Acarbose was found to be a safe and effective agent that could be used in cases with clomiphene-resistant PCOS.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15513975     DOI: 10.1093/humrep/deh580

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  7 in total

1.  History of infertility and risk of type 2 diabetes mellitus: a prospective cohort study.

Authors:  Deirdre K Tobias; Audrey J Gaskins; Stacey A Missmer; Frank B Hu; JoAnn E Manson; Germaine M Buck Louis; Cuilin Zhang; Jorge E Chavarro
Journal:  Diabetologia       Date:  2015-01-18       Impact factor: 10.122

2.  ROLE OF INSULIN SENSITIZERS ON CARDIOVASCULAR RISK FACTORS IN POLYCYSTIC OVARIAN SYNDROME: A META-ANALYSIS.

Authors:  Tina K Thethi; Bonnie Katalenich; Prathima Nagireddy; Pankdeep Chabbra; Nitesh Kuhadiya; Vivian Fonseca
Journal:  Endocr Pract       Date:  2015-02-25       Impact factor: 3.443

3.  The comparative effectiveness of 55 interventions in obese patients with polycystic ovary syndrome: A network meta-analysis of 101 randomized trials.

Authors:  Mohamed Abdel-Maboud; Amr Menshawy; Elfatih A Hasabo; Mohamed Ibrahim Abdelraoof; Mohamed Alshandidy; Muhammad Eid; Esraa Menshawy; Oumaima Outani; Ahmed Menshawy
Journal:  PLoS One       Date:  2021-07-19       Impact factor: 3.240

4.  The role of lipid and carbohydrate digestive enzyme inhibitors in the management of obesity: a review of current and emerging therapeutic agents.

Authors:  Sonia A Tucci; Emma J Boyland; Jason Cg Halford
Journal:  Diabetes Metab Syndr Obes       Date:  2010-05-10       Impact factor: 3.168

5.  Pharmacological and non-pharmacological strategies for obese women with subfertility.

Authors:  Seyed Abdolvahab Taghavi; Madelon van Wely; Shayesteh Jahanfar; Fatemeh Bazarganipour
Journal:  Cochrane Database Syst Rev       Date:  2021-03-25

6.  Comparing the Effect of Metformin and Acarbose Accompanying Clomiphene on the Successful Ovulation Induction in Infertile Women with Polycystic Ovary Syndrome.

Authors:  Masomeh Rezai; Mohmmad Jamshidi; Robabeh Mohammadbeigi; Fariba Seyedoshohadaei; Somaye Mohammadipour; Ghobad Moradi
Journal:  Glob J Health Sci       Date:  2016-09-01

7.  Pregnancies following the use of sequential treatment of metformin and incremental doses of letrozole in clomiphen-resistant women with polycystic ovary syndrome.

Authors:  Azam Azargoon; Jafar Alavy Toussy; Fakhry Fakhr Darbanan
Journal:  Iran J Reprod Med       Date:  2012-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.